<DISEASE></DISEASE> were treated with <DRUG></DRUG>	0.972136411	$DISEASE were treated with $DRUG
<DRUG></DRUG> in the treatment of <DISEASE></DISEASE>	0.9562639352	$DRUG in the treatment of $DISEASE
leukemia -lrb- <DISEASE></DISEASE> -rrb- ,	0.8948466525	leukemia -lrb- $DISEASE -rrb- ,
<DRUG></DRUG> for the treatment of <DISEASE></DISEASE>	0.8892685984	$DRUG for the treatment of $DISEASE
treatment of <DISEASE></DISEASE> -lrb- <DISEASE></DISEASE> -rrb-	0.8842636842	treatment of $DISEASE -lrb- $DISEASE -rrb-
treatment of <DISEASE></DISEASE> ,	0.8828484059	treatment of $DISEASE ,
<DRUG></DRUG> for the prevention of <DISEASE></DISEASE>	0.8651383348	$DRUG for the prevention of $DISEASE
<DISEASE></DISEASE> patients treated with <DRUG></DRUG>	0.8527646225	$DISEASE patients treated with $DRUG
treatment of <DISEASE></DISEASE>	0.8449476809	treatment of $DISEASE
-rrb- in the treatment of <DISEASE></DISEASE>	0.8401983963	-rrb- in the treatment of $DISEASE
treatment of acute <DISEASE></DISEASE>	0.8275487721	treatment of acute $DISEASE
<DRUG></DRUG> for postoperative <DISEASE></DISEASE> relief	0.8063929837	$DRUG for postoperative $DISEASE relief
cell lung cancer -lrb- <DISEASE></DISEASE> -rrb-	0.8058532773	cell lung cancer -lrb- $DISEASE -rrb-
patients with severe <DISEASE></DISEASE>	0.8043314084	patients with severe $DISEASE
patients with chronic <DISEASE></DISEASE>	0.8033314084	patients with chronic $DISEASE
mh - <DISEASE></DISEASE> / * drug	0.7907311682	mh - $DISEASE / * drug
chronic low back <DISEASE></DISEASE>	0.7694295758	chronic low back $DISEASE
effective in the treatment of <DISEASE></DISEASE>	0.7664228411	effective in the treatment of $DISEASE
acute myeloid <DISEASE></DISEASE> -lrb-	0.7661484367	acute myeloid $DISEASE -lrb-
treatment of severe <DISEASE></DISEASE>	0.7550383864	treatment of severe $DISEASE
<DISEASE></DISEASE> -lrb- nhl -rrb-	0.7478158679	$DISEASE -lrb- nhl -rrb-
carinii pneumonia -lrb- <DISEASE></DISEASE> -rrb-	0.7464581784	carinii pneumonia -lrb- $DISEASE -rrb-
lymphocytic leukemia -lrb- <DISEASE></DISEASE> -rrb-	0.7395166138	lymphocytic leukemia -lrb- $DISEASE -rrb-
treatment of chronic <DISEASE></DISEASE>	0.7367041572	treatment of chronic $DISEASE
<DISEASE></DISEASE> on injection of <DRUG></DRUG>	0.7351042393	$DISEASE on injection of $DRUG
treatment of primary <DISEASE></DISEASE>	0.7277041572	treatment of primary $DISEASE
<DISEASE></DISEASE> necrosis factor alpha	0.7245649721	$DISEASE necrosis factor alpha
patients with knee <DISEASE></DISEASE> -lrb-	0.7154711211	patients with knee $DISEASE -lrb-
management of postoperative <DISEASE></DISEASE>	0.7081944093	management of postoperative $DISEASE
<DISEASE></DISEASE> -lrb- <DISEASE></DISEASE> -rrb-	0.7073920415	$DISEASE -lrb- $DISEASE -rrb-
<DISEASE></DISEASE> toxoid -lrb- <DRUG></DRUG> -rrb-	0.7065944914	$DISEASE toxoid -lrb- $DRUG -rrb-
children and adolescents with <DISEASE></DISEASE>	0.6932766898	children and adolescents with $DISEASE
patients with primary <DISEASE></DISEASE>	0.6893972308	patients with primary $DISEASE
patients with knee <DISEASE></DISEASE>	0.6819907597	patients with knee $DISEASE
postoperative <DISEASE></DISEASE> and vomiting -lrb- ponv -rrb-	0.6704956015	postoperative $DISEASE and vomiting -lrb- ponv -rrb-
patients with stable <DISEASE></DISEASE>	0.6698874829	patients with stable $DISEASE
patients with septic <DISEASE></DISEASE>	0.6688874829	patients with septic $DISEASE
heterozygous familial <DISEASE></DISEASE>	0.6674102395	heterozygous familial $DISEASE
<DISEASE></DISEASE> toxoid -lrb- <DRUG></DRUG>	0.6634050091	$DISEASE toxoid -lrb- $DRUG
patients with moderate-to-severe <DISEASE></DISEASE>	0.6532833163	patients with moderate-to-severe $DISEASE
patients with acute myeloid <DISEASE></DISEASE> -lrb- aml -rrb-	0.6512100866	patients with acute myeloid $DISEASE -lrb- aml -rrb-
acute myelogenous <DISEASE></DISEASE> -lrb- aml -rrb-	0.6415600196	acute myelogenous $DISEASE -lrb- aml -rrb-
acute lymphoblastic <DISEASE></DISEASE> -lrb- all -rrb-	0.6415600196	acute lymphoblastic $DISEASE -lrb- all -rrb-
chronic lymphocytic leukemia -lrb- <DISEASE></DISEASE> -rrb-	0.6410600196	chronic lymphocytic leukemia -lrb- $DISEASE -rrb-
acute myelogenous leukemia -lrb- <DISEASE></DISEASE> -rrb-	0.6400600196	acute myelogenous leukemia -lrb- $DISEASE -rrb-
non-small cell lung cancer -lrb- <DISEASE></DISEASE> -rrb-	0.6399171625	non-small cell lung cancer -lrb- $DISEASE -rrb-
small cell lung cancer -lrb- <DISEASE></DISEASE> -rrb-	0.6399171625	small cell lung cancer -lrb- $DISEASE -rrb-
non-small-cell lung cancer -lrb- <DISEASE></DISEASE> -rrb-	0.6394171625	non-small-cell lung cancer -lrb- $DISEASE -rrb-
idiopathic thrombocytopenic purpura -lrb- <DISEASE></DISEASE> -rrb-	0.6388100196	idiopathic thrombocytopenic purpura -lrb- $DISEASE -rrb-
<DISEASE></DISEASE> carinii pneumonia	0.6306713751	$DISEASE carinii pneumonia
prophylaxis of <DISEASE></DISEASE> carinii pneumonia	0.630562725	prophylaxis of $DISEASE carinii pneumonia
<DRUG></DRUG> -lrb- mg/day -rrb- ,	0.6298244068	$DRUG -lrb- mg/day -rrb- ,
patients with mild to moderate essential <DISEASE></DISEASE>	0.6266401222	patients with mild to moderate essential $DISEASE
<DISEASE></DISEASE> or schizoaffective disorder	0.6199972651	$DISEASE or schizoaffective disorder
treatment of <DISEASE></DISEASE> in patients	0.618703843	treatment of $DISEASE in patients
congestive heart failure -lrb- <DISEASE></DISEASE> -rrb-	0.6143695434	congestive heart failure -lrb- $DISEASE -rrb-
common variable <DISEASE></DISEASE> -lrb- cvid -rrb-	0.6137624006	common variable $DISEASE -lrb- cvid -rrb-
attention-deficit hyperactivity disorder -lrb- <DISEASE></DISEASE> -rrb-	0.6137624006	attention-deficit hyperactivity disorder -lrb- $DISEASE -rrb-
attention deficit hyperactivity disorder -lrb- <DISEASE></DISEASE> -rrb-	0.6137624006	attention deficit hyperactivity disorder -lrb- $DISEASE -rrb-
safety and efficacy of <DRUG></DRUG>	0.6121190243	safety and efficacy of $DRUG
patients with mild to moderate <DISEASE></DISEASE>	0.6117357932	patients with mild to moderate $DISEASE
efficacy and safety of <DRUG></DRUG> -lrb-	0.6047722828	efficacy and safety of $DRUG -lrb-
<DISEASE></DISEASE> necrosis factor-alpha	0.6021881742	$DISEASE necrosis factor-alpha
<DRUG></DRUG> -lrb- <DRUG></DRUG> -rrb-	0.5986465905	$DRUG -lrb- $DRUG -rrb-
acute lymphoblastic <DISEASE></DISEASE> -lrb-	0.5871187597	acute lymphoblastic $DISEASE -lrb-
background : <DISEASE></DISEASE>	0.5762062864	background : $DISEASE
<DRUG></DRUG> for the treatment	0.5684471048	$DRUG for the treatment
patients with stable <DISEASE></DISEASE> pectoris	0.5577907008	patients with stable $DISEASE pectoris
patients with essential <DISEASE></DISEASE>	0.5560102521	patients with essential $DISEASE
-lrb- <DRUG></DRUG> -rrb- sb	0.5496259225	-lrb- $DRUG -rrb- sb
efficacy and safety of <DRUG></DRUG>	0.5467829021	efficacy and safety of $DRUG
<DRUG></DRUG> -lrb- <DRUG></DRUG> -rrb- ,	0.5308948995	$DRUG -lrb- $DRUG -rrb- ,
<DRUG></DRUG> in the management	0.526987068	$DRUG in the management
toxoid -lrb- <DRUG></DRUG> -rrb- ,	0.5191127076	toxoid -lrb- $DRUG -rrb- ,
effective as <DRUG></DRUG>	0.492427185	effective as $DRUG
<DRUG></DRUG> monitoring -lrb- cgm -rrb-	0.4842828034	$DRUG monitoring -lrb- cgm -rrb-
myelogenous leukemia -lrb- <DISEASE></DISEASE> -rrb-	0.4822628358	myelogenous leukemia -lrb- $DISEASE -rrb-
<DRUG></DRUG> -lrb-	0.4759765688	$DRUG -lrb-
intravenous -lrb- iv -rrb- <DRUG></DRUG>	0.4740867128	intravenous -lrb- iv -rrb- $DRUG
efficacy and tolerability of <DRUG></DRUG>	0.466317482	efficacy and tolerability of $DRUG
patients in the <DRUG></DRUG> group	0.4592280265	patients in the $DRUG group
-lrb- <DRUG></DRUG> -rrb-	0.4546409322	-lrb- $DRUG -rrb-
efficacy of <DRUG></DRUG> in the treatment	0.4470005731	efficacy of $DRUG in the treatment
role of <DRUG></DRUG>	0.4452632977	role of $DRUG
<DRUG></DRUG> is one	0.4422111034	$DRUG is one
<DISEASE></DISEASE> -lrb- <DISEASE></DISEASE> -rrb- ,	0.429125216	$DISEASE -lrb- $DISEASE -rrb- ,
background : <DRUG></DRUG> -lrb- <DRUG></DRUG> -rrb-	0.4260052908	background : $DRUG -lrb- $DRUG -rrb-
<DRUG></DRUG> -rrb- in patients	0.4089862393	$DRUG -rrb- in patients
<DRUG></DRUG> for the prevention	0.4049523309	$DRUG for the prevention
intravenous immunoglobulin -lrb- <DRUG></DRUG> -rrb-	0.3997456327	intravenous immunoglobulin -lrb- $DRUG -rrb-
intrathecal <DRUG></DRUG> -lrb- itb -rrb-	0.3982456327	intrathecal $DRUG -lrb- itb -rrb-
intravenous <DRUG></DRUG> -lrb- ivig -rrb-	0.3972456327	intravenous $DRUG -lrb- ivig -rrb-
continuous <DRUG></DRUG> monitoring -lrb- cgm -rrb-	0.3969956327	continuous $DRUG monitoring -lrb- cgm -rrb-
patients with <DISEASE></DISEASE> -lrb- <DISEASE></DISEASE> -rrb-	0.3917243119	patients with $DISEASE -lrb- $DISEASE -rrb-
knee <DISEASE></DISEASE> -lrb- <DISEASE></DISEASE> -rrb-	0.3834909376	knee $DISEASE -lrb- $DISEASE -rrb-
nausea and <DISEASE></DISEASE> -lrb-	0.3823909376	nausea and $DISEASE -lrb-
prophylaxis of <DISEASE></DISEASE> carinii	0.3745560018	prophylaxis of $DISEASE carinii
<DISEASE></DISEASE> -lrb- aml -rrb-	0.3714778053	$DISEASE -lrb- aml -rrb-
patients with knee <DISEASE></DISEASE> -lrb- <DISEASE></DISEASE> -rrb-	0.3682899511	patients with knee $DISEASE -lrb- $DISEASE -rrb-
recurrent venous <DISEASE></DISEASE>	0.3674060018	recurrent venous $DISEASE
patients with <DISEASE></DISEASE> ,	0.3662414696	patients with $DISEASE ,
mh - <DISEASE></DISEASE>	0.3544742741	mh - $DISEASE
<DRUG></DRUG> -lrb- pza -rrb-	0.3454701889	$DRUG -lrb- pza -rrb-
acute myeloid <DISEASE></DISEASE>	0.3413892233	acute myeloid $DISEASE
patients treated with <DRUG></DRUG>	0.3374413814	patients treated with $DRUG
<DISEASE></DISEASE> -lrb- all -rrb-	0.31184487	$DISEASE -lrb- all -rrb-
<DISEASE></DISEASE> on <DRUG></DRUG> injection	0.30884487	$DISEASE on $DRUG injection
<DISEASE></DISEASE> and vomiting -lrb-	0.30684487	$DISEASE and vomiting -lrb-
patients who received <DRUG></DRUG>	0.3049828105	patients who received $DRUG
lung cancer -lrb- <DISEASE></DISEASE> -rrb-	0.3044138879	lung cancer -lrb- $DISEASE -rrb-
venous <DISEASE></DISEASE> -lrb- vte -rrb-	0.3044138879	venous $DISEASE -lrb- vte -rrb-
acute myelogenous <DISEASE></DISEASE> -lrb- aml	0.3021638879	acute myelogenous $DISEASE -lrb- aml
<DRUG></DRUG> in patients with <DISEASE></DISEASE>	0.2988668235	$DRUG in patients with $DISEASE
-rrb- and <DRUG></DRUG> -lrb- <DRUG></DRUG> -rrb-	0.2948573002	-rrb- and $DRUG -lrb- $DRUG -rrb-
prevention and treatment of <DISEASE></DISEASE>	0.2923229898	prevention and treatment of $DISEASE
treatment of <DISEASE></DISEASE> with <DRUG></DRUG>	0.2912875919	treatment of $DISEASE with $DRUG
patients with <DISEASE></DISEASE> who	0.2901974612	patients with $DISEASE who
<DRUG></DRUG> for treatment of <DISEASE></DISEASE>	0.2874588221	$DRUG for treatment of $DISEASE
patients with acute <DISEASE></DISEASE>	0.2872450803	patients with acute $DISEASE
<DISEASE></DISEASE> in patients who	0.2862450803	$DISEASE in patients who
-lrb- <DISEASE></DISEASE> -rrb- ,	0.28592434	-lrb- $DISEASE -rrb- ,
acute myeloid leukemia -lrb- <DISEASE></DISEASE> -rrb-	0.2848327435	acute myeloid leukemia -lrb- $DISEASE -rrb-
<DRUG></DRUG> on postoperative <DISEASE></DISEASE>	0.2848098118	$DRUG on postoperative $DISEASE
patients with multiple <DISEASE></DISEASE>	0.2847422378	patients with multiple $DISEASE
patients with familial <DISEASE></DISEASE>	0.2822220912	patients with familial $DISEASE
disorder -lrb- <DISEASE></DISEASE> -rrb-	0.28192434	disorder -lrb- $DISEASE -rrb-
disorder -lrb- <DISEASE></DISEASE> -rrb- ,	0.2818132419	disorder -lrb- $DISEASE -rrb- ,
-rrb- in patients with <DISEASE></DISEASE>	0.2793685232	-rrb- in patients with $DISEASE
treatment of patients with <DISEASE></DISEASE>	0.2783685232	treatment of patients with $DISEASE
leukemia -lrb- <DISEASE></DISEASE> -rrb-	0.2762056451	leukemia -lrb- $DISEASE -rrb-
infection -lrb- <DISEASE></DISEASE> -rrb-	0.2762056451	infection -lrb- $DISEASE -rrb-
treatment of secondary <DISEASE></DISEASE>	0.2762056451	treatment of secondary $DISEASE
<DISEASE></DISEASE> is a common	0.274317608	$DISEASE is a common
postoperative nausea and <DISEASE></DISEASE>	0.2739748759	postoperative nausea and $DISEASE
prevention of venous <DISEASE></DISEASE>	0.2739748759	prevention of venous $DISEASE
<DISEASE></DISEASE> -lrb- ponv -rrb-	0.2714604652	$DISEASE -lrb- ponv -rrb-
hyperactivity disorder -lrb- <DISEASE></DISEASE> -rrb-	0.270478306	hyperactivity disorder -lrb- $DISEASE -rrb-
multiple <DISEASE></DISEASE> -lrb- mm -rrb-	0.268978306	multiple $DISEASE -lrb- mm -rrb-
graft-versus-host disease -lrb- <DISEASE></DISEASE> -rrb-	0.268978306	graft-versus-host disease -lrb- $DISEASE -rrb-
familial <DISEASE></DISEASE> -lrb- fh -rrb-	0.2683354489	familial $DISEASE -lrb- fh -rrb-
secondary <DISEASE></DISEASE> -lrb- shpt -rrb-	0.2683354489	secondary $DISEASE -lrb- shpt -rrb-
prophylaxis against <DISEASE></DISEASE> carinii pneumonia	0.268228306	prophylaxis against $DISEASE carinii pneumonia
non-hodgkin 's <DISEASE></DISEASE> -lrb- nhl	0.267728306	non-hodgkin 's $DISEASE -lrb- nhl
cardiac <DISEASE></DISEASE> suppression trial	0.2676042523	cardiac $DISEASE suppression trial
<DISEASE></DISEASE> clinical trials group	0.2674128461	$DISEASE clinical trials group
<DRUG></DRUG> in patients	0.2660522067	$DRUG in patients
breakthrough cancer <DISEASE></DISEASE>	0.265915785	breakthrough cancer $DISEASE
erosive <DISEASE></DISEASE> esophagitis	0.265915785	erosive $DISEASE esophagitis
mantle cell <DISEASE></DISEASE>	0.265915785	mantle cell $DISEASE
patients with major <DISEASE></DISEASE>	0.2622590369	patients with major $DISEASE
patients with mild <DISEASE></DISEASE>	0.2622590369	patients with mild $DISEASE
<DISEASE></DISEASE> cell lines	0.2609608981	$DISEASE cell lines
<DISEASE></DISEASE> during pregnancy	0.2609608981	$DISEASE during pregnancy
<DISEASE></DISEASE> or schizoaffective	0.2609608981	$DISEASE or schizoaffective
patients with mild-to-moderate <DISEASE></DISEASE>	0.2597388904	patients with mild-to-moderate $DISEASE
patients with gastroesophageal <DISEASE></DISEASE> disease	0.2596513743	patients with gastroesophageal $DISEASE disease
patients with secondary <DISEASE></DISEASE>	0.2593066559	patients with secondary $DISEASE
patients with refractory <DISEASE></DISEASE>	0.2593066559	patients with refractory $DISEASE
patients with advanced <DISEASE></DISEASE>	0.2583066559	patients with advanced $DISEASE
<DISEASE></DISEASE> necrosis factor	0.2580085171	$DISEASE necrosis factor
<DISEASE></DISEASE> cell line	0.2580085171	$DISEASE cell line
patients with <DISEASE></DISEASE> pectoris	0.2576912713	patients with $DISEASE pectoris
<DISEASE></DISEASE> zoster virus	0.2575085171	$DISEASE zoster virus
patients with <DISEASE></DISEASE> oesophagitis	0.2571912713	patients with $DISEASE oesophagitis
<DISEASE></DISEASE> after laparoscopic	0.2570085171	$DISEASE after laparoscopic
<DISEASE></DISEASE> at rest	0.2549608981	$DISEASE at rest
obsessive-compulsive disorder -lrb- <DISEASE></DISEASE> -rrb-	0.251930687	obsessive-compulsive disorder -lrb- $DISEASE -rrb-
-lrb- <DISEASE></DISEASE> -rrb-	0.2510989031	-lrb- $DISEASE -rrb-
<DISEASE></DISEASE> -lrb- vte -rrb-	0.2508479063	$DISEASE -lrb- vte -rrb-
prevention of <DISEASE></DISEASE>	0.2480408268	prevention of $DISEASE
-lrb- <DISEASE></DISEASE> -rrb- prophylaxis	0.24787423	-lrb- $DISEASE -rrb- prophylaxis
venous <DISEASE></DISEASE> -lrb-	0.2470276488	venous $DISEASE -lrb-
attention-deficit/hyperactivity disorder -lrb- <DISEASE></DISEASE> -rrb-	0.246930687	attention-deficit/hyperactivity disorder -lrb- $DISEASE -rrb-
management of <DISEASE></DISEASE>	0.2465408268	management of $DISEASE
treatment for severe <DISEASE></DISEASE>	0.24637423	treatment for severe $DISEASE
patients with <DISEASE></DISEASE> -lrb-	0.2455863602	patients with $DISEASE -lrb-
<DRUG></DRUG> for <DISEASE></DISEASE> relief	0.2418363588	$DRUG for $DISEASE relief
treatment of neuropathic <DISEASE></DISEASE>	0.2417700633	treatment of neuropathic $DISEASE
<DISEASE></DISEASE> toxoid -lrb-	0.2408080975	$DISEASE toxoid -lrb-
treatment of <DISEASE></DISEASE> oesophagitis	0.2395392941	treatment of $DISEASE oesophagitis
leukaemia -lrb- <DISEASE></DISEASE> -rrb-	0.2395392941	leukaemia -lrb- $DISEASE -rrb-
thrombocytopenia -lrb- <DISEASE></DISEASE> -rrb-	0.2395392941	thrombocytopenia -lrb- $DISEASE -rrb-
mild to moderate essential <DISEASE></DISEASE>	0.2385883342	mild to moderate essential $DISEASE
carcinoma -lrb- <DISEASE></DISEASE> -rrb-	0.2385392941	carcinoma -lrb- $DISEASE -rrb-
acute myeloid <DISEASE></DISEASE> -lrb- aml -rrb-	0.2362688856	acute myeloid $DISEASE -lrb- aml -rrb-
gastroesophageal <DISEASE></DISEASE> disease -lrb- <DISEASE></DISEASE> -rrb-	0.2343455878	gastroesophageal $DISEASE disease -lrb- $DISEASE -rrb-
acute lymphoblastic <DISEASE></DISEASE>	0.232087346	acute lymphoblastic $DISEASE
chronic idiopathic <DISEASE></DISEASE>	0.232087346	chronic idiopathic $DISEASE
acute myelogenous <DISEASE></DISEASE>	0.232087346	acute myelogenous $DISEASE
gastro-oesophageal <DISEASE></DISEASE> disease	0.2314802032	gastro-oesophageal $DISEASE disease
out-of-hospital cardiac <DISEASE></DISEASE>	0.2314802032	out-of-hospital cardiac $DISEASE
human <DISEASE></DISEASE> virus	0.2314802032	human $DISEASE virus
stable <DISEASE></DISEASE> pectoris	0.2314802032	stable $DISEASE pectoris
propofol injection <DISEASE></DISEASE>	0.2314802032	propofol injection $DISEASE
low back <DISEASE></DISEASE>	0.2314802032	low back $DISEASE
<DRUG></DRUG> group -lrb-	0.2311203002	$DRUG group -lrb-
non-hodgkin 's <DISEASE></DISEASE>	0.2304802032	non-hodgkin 's $DISEASE
toxoid -lrb- <DRUG></DRUG> -rrb-	0.2289066704	toxoid -lrb- $DRUG -rrb-
postoperative <DISEASE></DISEASE> in patients	0.228162403	postoperative $DISEASE in patients
-rrb- rn - -lrb- <DRUG></DRUG> -rrb- rn	0.2276759012	-rrb- rn - -lrb- $DRUG -rrb- rn
<DRUG></DRUG> -lrb- ara-c -rrb-	0.2276759012	$DRUG -lrb- ara-c -rrb-
-lrb- <DRUG></DRUG> -rrb- rn	0.2276759012	-lrb- $DRUG -rrb- rn
<DRUG></DRUG> mg/m -lrb- -rrb-	0.2276759012	$DRUG mg/m -lrb- -rrb-
injection of liposomal <DRUG></DRUG>	0.2276759012	injection of liposomal $DRUG
<DRUG></DRUG> -rrb- sb	0.2276759012	$DRUG -rrb- sb
% <DRUG></DRUG> with epinephrine	0.2276759012	% $DRUG with epinephrine
<DISEASE></DISEASE> objective	0.2257066184	$DISEASE objective
<DISEASE></DISEASE> on injection	0.2217542374	$DISEASE on injection
management of chronic <DISEASE></DISEASE>	0.221491675	management of chronic $DISEASE
failure -lrb- <DISEASE></DISEASE> -rrb-	0.2187224443	failure -lrb- $DISEASE -rrb-
acute and chronic <DISEASE></DISEASE>	0.2187224443	acute and chronic $DISEASE
<DRUG></DRUG> in the treatment	0.218560531	$DRUG in the treatment
diabetes -lrb- <DISEASE></DISEASE> -rrb-	0.2177700633	diabetes -lrb- $DISEASE -rrb-
pneumonia -lrb- <DISEASE></DISEASE> -rrb-	0.2167700633	pneumonia -lrb- $DISEASE -rrb-
moderate to severe <DISEASE></DISEASE>	0.216491675	moderate to severe $DISEASE
significant reduction in <DISEASE></DISEASE>	0.216491675	significant reduction in $DISEASE
treatment of mild-to-moderate <DISEASE></DISEASE>	0.216491675	treatment of mild-to-moderate $DISEASE
patient with <DISEASE></DISEASE>	0.2155920669	patient with $DISEASE
adult patients with <DISEASE></DISEASE>	0.2150484885	adult patients with $DISEASE
<DISEASE></DISEASE> during injection	0.214325561	$DISEASE during injection
moderate essential <DISEASE></DISEASE>	0.214039727	moderate essential $DISEASE
nausea and <DISEASE></DISEASE>	0.2135920669	nausea and $DISEASE
chronic plaque <DISEASE></DISEASE>	0.209039727	chronic plaque $DISEASE
patients with <DISEASE></DISEASE>	0.2085010422	patients with $DISEASE
common variable <DISEASE></DISEASE>	0.2084325841	common variable $DISEASE
severe plaque <DISEASE></DISEASE>	0.2084325841	severe plaque $DISEASE
chronic stable <DISEASE></DISEASE>	0.208087346	chronic stable $DISEASE
onset of <DISEASE></DISEASE>	0.2065444479	onset of $DISEASE
postoperative <DISEASE></DISEASE> management	0.2063725156	postoperative $DISEASE management
postoperative <DISEASE></DISEASE> relief	0.2063725156	postoperative $DISEASE relief
severity of <DISEASE></DISEASE>	0.2015920669	severity of $DISEASE
fludarabine , <DRUG></DRUG> ,	0.1995756711	fludarabine , $DRUG ,
essential <DISEASE></DISEASE> -lrb-	0.1969879003	essential $DISEASE -lrb-
knee <DISEASE></DISEASE> -lrb-	0.1969879003	knee $DISEASE -lrb-
prevalence of <DISEASE></DISEASE>	0.1969402812	prevalence of $DISEASE
<DISEASE></DISEASE> in patients	0.1771061843	$DISEASE in patients
postoperative <DISEASE></DISEASE>	0.1762438492	postoperative $DISEASE
<DRUG></DRUG> -lrb- <DRUG></DRUG> -rrb- treatment	0.1723644396	$DRUG -lrb- $DRUG -rrb- treatment
<DISEASE></DISEASE> who	0.1666962302	$DISEASE who
mild to moderate <DISEASE></DISEASE>	0.1614266256	mild to moderate $DISEASE
<DISEASE></DISEASE> -lrb- p <	0.1596747929	$DISEASE -lrb- p <
<DRUG></DRUG> -lrb- mg/kg -rrb-	0.1536847076	$DRUG -lrb- mg/kg -rrb-
factor viii -lrb- <DRUG></DRUG> -rrb-	0.1524539384	factor viii -lrb- $DRUG -rrb-
<DRUG></DRUG> -lrb- cbz -rrb-	0.1524539384	$DRUG -lrb- cbz -rrb-
<DRUG></DRUG> -lrb- pht -rrb-	0.1524539384	$DRUG -lrb- pht -rrb-
mitomycin c -lrb- <DRUG></DRUG> -rrb-	0.1524539384	mitomycin c -lrb- $DRUG -rrb-
effects of <DRUG></DRUG> -lrb-	0.1511205597	effects of $DRUG -lrb-
effect of <DRUG></DRUG> -lrb-	0.1511205597	effect of $DRUG -lrb-
<DISEASE></DISEASE> -lrb-	0.1505638944	$DISEASE -lrb-
-lrb- <DRUG></DRUG> -rrb- ,	0.1463667736	-lrb- $DRUG -rrb- ,
effect of <DRUG></DRUG>	0.1419381527	effect of $DRUG
<DRUG></DRUG> in the prevention	0.1419381527	$DRUG in the prevention
combination of <DRUG></DRUG>	0.1337780147	combination of $DRUG
effects of <DRUG></DRUG>	0.1263506598	effects of $DRUG
<DRUG></DRUG> : a new	0.1219157925	$DRUG : a new
<DRUG></DRUG> -lrb- ap -rrb-	0.1205183566	$DRUG -lrb- ap -rrb-
lower in the <DRUG></DRUG> group	0.1202491258	lower in the $DRUG group
combination therapy with <DRUG></DRUG>	0.1202491258	combination therapy with $DRUG
<DRUG></DRUG> -lrb- dex -rrb-	0.1200183566	$DRUG -lrb- dex -rrb-
continuous infusion of <DRUG></DRUG>	0.1200183566	continuous infusion of $DRUG
efficacy of <DRUG></DRUG>	0.1159311917	efficacy of $DRUG
combination with <DRUG></DRUG>	0.1133649778	combination with $DRUG
background : <DRUG></DRUG> ,	0.1117803487	background : $DRUG ,
versus <DRUG></DRUG> in the treatment	0.1117803487	versus $DRUG in the treatment
acid -lrb- <DRUG></DRUG> -rrb-	0.1097803487	acid -lrb- $DRUG -rrb-
<DRUG></DRUG> is an effective	0.1088815068	$DRUG is an effective
<DRUG></DRUG> is a safe	0.1076507375	$DRUG is a safe
agents such as <DRUG></DRUG>	0.1076507375	agents such as $DRUG
all-trans-retinoic acid -lrb- <DRUG></DRUG> -rrb-	0.1069707375	all-trans-retinoic acid -lrb- $DRUG -rrb-
immunoglobulin -lrb- <DRUG></DRUG> -rrb-	0.1069707375	immunoglobulin -lrb- $DRUG -rrb-
high doses of <DRUG></DRUG>	0.1069707375	high doses of $DRUG
<DRUG></DRUG> -lrb- mph -rrb-	0.1069707375	$DRUG -lrb- mph -rrb-
<DRUG></DRUG> -lrb- t -rrb-	0.1062015068	$DRUG -lrb- t -rrb-
different doses of <DRUG></DRUG>	0.1030183566	different doses of $DRUG
<DRUG></DRUG> -lrb- itb -rrb-	0.1030183566	$DRUG -lrb- itb -rrb-
effective than <DRUG></DRUG>	0.1011730853	effective than $DRUG
safety of <DRUG></DRUG>	0.0997166158	safety of $DRUG
intravenous <DRUG></DRUG> -lrb- ivig	0.0931639854	intravenous $DRUG -lrb- ivig
<DRUG></DRUG> is effective	0.0930927296	$DRUG is effective
tolerability of <DRUG></DRUG>	0.0914864571	tolerability of $DRUG
conclusion : <DRUG></DRUG>	0.090426063	conclusion : $DRUG
background : <DRUG></DRUG>	0.0901403487	background : $DRUG
introduction : <DRUG></DRUG>	0.0891952937	introduction : $DRUG
objective : <DRUG></DRUG>	0.0881403487	objective : $DRUG
<DRUG></DRUG> -rrb-	0.0632033444	$DRUG -rrb-
